File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Identification of an anti-viral compound with inhibitory effects on influenza replication

TitleIdentification of an anti-viral compound with inhibitory effects on influenza replication
Authors
Issue Date2013
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/cytokine
Citation
The 11th Joint Meeting ofJoint Annual Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR), San Francisco, CA., 29 September-3 October 2013. In Cytokine, 2013, v. 63 n. 3, p. 311-312, abstract no. 288 How to Cite?
AbstractIn light of the recent novel H1N1 virus epidemic, virus resistance to currently approved antiviral medications has become a global health concern. Since almost all circulating strains of influenza A viruses are resistant to either adamantanes or neuraminidase inhibitors, new therapeutic approaches and means to discover new antiviral agents are critical to address the issue of recurring drug resistance. We postulate that computational molecular docking provides an efficient and innovative approach to examine small molecules against influenza viruses. We have identified a potent inhibitor of the H5N1 neuraminidase protein from a library of 23,000 compounds. This compound demonstrated anti-viral activity efficacy in vitro across a number of cell-lines assays in H5N1, H1N1, H9N2/G1, H3N2 and the oseltamivir-resistant H1N1 virus while the compound itself did not show any cytotoxicity. The underlying mechanisms including immunoregulation, upstream signalling pathways and neuraminidase inhibitory activity were also studied. It was found that the compound inhibit the viral titers via inhibiting the neuraminidase activity. Upon successful demonstration of the effectiveness of the compound in the cell culture model, we further validated the anti-influenza effect of the compound in a mouse model. BALB/c mice were administrated once daily with the compound or diluent control (DMSO). They were then intranasally infected with A/PR/8/34 influenza virus. The mice were treated with the compound or DMSO through oral gavage for five more days starting from 8 h post-infection. Our results showed that the compound prolonged the life span and increased the survival rate of the mice. These results demonstrated that the compound screened from molecular docking is a new potential drug candidate for inhibiting viral replications of different influenza viruses. Copyright © 2013 Published by Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/206045
ISSN
2015 Impact Factor: 2.94
2015 SCImago Journal Rankings: 1.294
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, LHen_US
dc.contributor.authorLaw, HYen_US
dc.contributor.authorOr, CTen_US
dc.contributor.authorAu, KYen_US
dc.contributor.authorLi, CBen_US
dc.contributor.authorLau, ASYen_US
dc.date.accessioned2014-10-20T11:47:22Z-
dc.date.available2014-10-20T11:47:22Z-
dc.date.issued2013en_US
dc.identifier.citationThe 11th Joint Meeting ofJoint Annual Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR), San Francisco, CA., 29 September-3 October 2013. In Cytokine, 2013, v. 63 n. 3, p. 311-312, abstract no. 288en_US
dc.identifier.issn1043-4666-
dc.identifier.urihttp://hdl.handle.net/10722/206045-
dc.description.abstractIn light of the recent novel H1N1 virus epidemic, virus resistance to currently approved antiviral medications has become a global health concern. Since almost all circulating strains of influenza A viruses are resistant to either adamantanes or neuraminidase inhibitors, new therapeutic approaches and means to discover new antiviral agents are critical to address the issue of recurring drug resistance. We postulate that computational molecular docking provides an efficient and innovative approach to examine small molecules against influenza viruses. We have identified a potent inhibitor of the H5N1 neuraminidase protein from a library of 23,000 compounds. This compound demonstrated anti-viral activity efficacy in vitro across a number of cell-lines assays in H5N1, H1N1, H9N2/G1, H3N2 and the oseltamivir-resistant H1N1 virus while the compound itself did not show any cytotoxicity. The underlying mechanisms including immunoregulation, upstream signalling pathways and neuraminidase inhibitory activity were also studied. It was found that the compound inhibit the viral titers via inhibiting the neuraminidase activity. Upon successful demonstration of the effectiveness of the compound in the cell culture model, we further validated the anti-influenza effect of the compound in a mouse model. BALB/c mice were administrated once daily with the compound or diluent control (DMSO). They were then intranasally infected with A/PR/8/34 influenza virus. The mice were treated with the compound or DMSO through oral gavage for five more days starting from 8 h post-infection. Our results showed that the compound prolonged the life span and increased the survival rate of the mice. These results demonstrated that the compound screened from molecular docking is a new potential drug candidate for inhibiting viral replications of different influenza viruses. Copyright © 2013 Published by Elsevier Ltd.-
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/cytokine-
dc.relation.ispartofCytokineen_US
dc.titleIdentification of an anti-viral compound with inhibitory effects on influenza replicationen_US
dc.typeConference_Paperen_US
dc.identifier.emailYang, LH: cindyy@hkucc.hku.hken_US
dc.identifier.emailLaw, HY: lawanna@hkucc.hku.hken_US
dc.identifier.emailOr, CT: h0414084@hkusua.hku.hken_US
dc.identifier.emailAu, KY: aukinyi@graduate.hku.hken_US
dc.identifier.emailLi, CB: jamesli@graduate.hku.hken_US
dc.identifier.emailLau, ASY: asylau@hku.hken_US
dc.identifier.authorityLi, CB=rp00496en_US
dc.identifier.authorityLau, ASY=rp00474en_US
dc.identifier.doi10.1016/j.cyto.2013.06.291-
dc.identifier.hkuros241322en_US
dc.identifier.hkuros266519-
dc.identifier.volume63-
dc.identifier.issue3-
dc.identifier.spage311, abstract no. 288-
dc.identifier.epage312-
dc.identifier.isiWOS:000324013700300-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats